Besides Covishield, four more Covid-19 vaccines are under preparation at the world’s largest vaccine company in Pune as demand from across the globe spikes.
The DCGI has given the nod for two vaccines and phase 1 of the vaccination process is expected to begin soon. Zydus Cadila’s vaccine candidate has also been cleared for phase 3 trials.
As we look ahead to immunisation in 2021, there is the fear of adverse reactions to the drugs as the vaccines have been tested for less than six months. But a framework exists to deal with such cases.
Three firms have applied for emergency use authorisation in India as of now. AIIMS’ Amit Dinda, who is a part of the Global Coalition for Regulatory Science Research, explains the regulatory nuances.
As the world awaits a panacea for Covid-19, pharma companies have their feet firmly on the accelerator to get people a safe vaccine to stem the spiral of death and illness looming over humanity.
